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A B S T R A C T   
Background: Elevation of serum uric acid (SUA) is associated with increased mortality; however, controversy 
exists regarding the nature of the relationship and differences between men and women. We explored re-
lationships of SUA levels with all-cause mortality in a large cohort of patients within the Irish health system. 
Methods: A retrospective cohort study of 26,525 participants was conducted using data from the National Kidney 
Disease Surveillance System. SUA was modelled in increments of 59.48 µmol/L (1 mg/dL), Cox’s proportional 
hazards model estimated hazard ratios (HRs) and 95% Confidence Intervals (CI), median lifetimes were also 
computed separately for men and women. Mortality patterns were further explored using penalised splines. 
Results: There were 1,288 (4.9%) deaths over a median follow-up of 5.1 years. In men, the risk of mortality was 
greatest for the lowest (<238 µmol/L) and highest (>535 µmol/L) categories [HR 2.35 (1.65–3.14) and HR 2.52 
(1.87–3.29) respectively]; the corresponding median lifetimes for men were reduced by 9.5 and 11.7 years 
respectively compared to the referent. In women, mortality risks were elevated for SUA >416 mol/L [HR 1.69 
(1.13–2.47) and beyond; the corresponding median lifetime for women were reduced by 5.9 years compared to 
the referent. Spline analysis revealed a U-shaped association between SUA and mortality in men, while for 
women, the pattern of association was J-shaped. 
Conclusion: Mortality patterns attributed to SUA differ between men and women. Optimal survival was associated 
with SUA concentrations of 304–454 µmol/L for men and < 409 µmol/L for women.   
1. Introduction 
It is widely considered that serum uric acid (SUA), the final break-
down product of purine metabolism in humans, may represent a major 
cardiovascular risk factor and contribute to adverse health outcomes 
and mortality [1–6]. Elevated concentrations of SUA have been impli-
cated in the development of hypertension, metabolic syndrome, type 2 
diabetes, coronary artery disease, left ventricular hypertrophy, atrial 
fibrillation, myocardial infarction, stroke, heart failure and chronic 
kidney disease [7]. Furthermore, large prospective observational studies 
have found a strong positive association between high levels of SUA and 
all-cause mortality suggesting a potentially causal relationship and a 
possible target for intervention. Nevertheless, several studies have sug-
gested that the relationship of SUA with major outcomes is not linear in 
shape and varies across studies [8–11]. Moreover, several recent studies 
have shown that patients with low SUA levels experienced higher 
mortality risks suggesting that low SUA levels may portend a poor 
prognosis in specific populations [12–14]. 
The true nature of the relationship between uric acid and mortality is 
important to clarify as treatment strategies that lower SUA may, on one 
hand, provide substantial benefits or, on the other hand, confer addi-
tional risk. At physiological levels, uric acid has both anti-oxidant 
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[15–18] and pro-oxidant properties [19,20], which suggests that, 
depending on the prevailing conditions, it may serve as either a bio-
logical defence mechanism or an inflammatory stressor [15–20]. Under 
normal circumstances, uric acid (as hydrogen urate) may function as an 
antioxidant and studies have shown that low levels of SUA damage the 
endothelium and induce oxidative stress–related disease such as hy-
pertension, diabetes mellitus, and kidney disease [21,22]. In contrast, 
uric acid can scavenge reactive oxygen species [17], chelate transition 
metals [15] and prevent the degradation of extracellular superoxide 
dismutase [16]. Thus, depending on the prevailing conditions, SUA may 
confer a beneficial or adverse function. The evidence to date raises 
suspicions that the relationship between SUA and mortality is not 
straightforward and may vary by sex, health status and degree of co-
morbidity [3-11]. 
The principal objectives of this study were to: examine the rela-
tionship between SUA and all-cause mortality among patients within the 
Irish health system; compare the shape of this relationship for men and 
women; and identify SUA threshold values for mortality and the optimal 
SUA range with greatest survival benefit. 
2. Methods 
2.1. Data source 
We utilised data from the National Kidney Disease Surveillance System 
(NKDSS), which monitors trends and outcomes of kidney disease in the 
Irish Health System [23]. The principal data sources include; regional 
laboratory information systems, which capture a comprehensive list of 
laboratory results from inpatients and outpatients within a designated 
health region; dialysis registers which capture clinical data on patients 
who progress to End Stage Kidney Disease (ESKD); and mortality data 
files from the national Central Statistics Office (CSO). The final merged 
dataset captured information on demographic characteristics, county of 
residence, primary location of patient supervision, multiple laboratory 
measures of health status, dialysis indicator variables and death. 
2.2. Cohort participants 
Patients who entered the health system from University Hospital 
Group Limerick (Midwest) in the Republic of Ireland, between January 
1st, 2006 and December 31st, 2012, were included and followed until 
December 31st, 2013. The analysis was restricted to adult participants, 
18 years of age or older, who had valid SUA measurements with con-
current biochemistry profiles and had vital status through 31st 
December 2013. 
2.3. Outcome 
The primary outcome was all-cause mortality (ICD-9 001.x–999.x or 
ICD-10 A00.x–Z99.x) as determined from national records provided by 
the CSO. The CSO oversees the collection and analysis of national data 
on mortality in the Republic of Ireland. The date of death and primary 
cause of death were available from the national mortality files. 
2.4. Exposure 
The primary exposure was SUA concentration recorded at first 
measurement within the health system for each patient. Serum uric acid 
(µmol/L) was measured using the uricase-peroxidase enzymatic method 
on an auto analyser in the laboratory data systems during the study 
period. Baseline characteristics for each participant were recorded at 
first entry into the health system during the recruitment period. Data 
were captured on age, sex, county of residence, health region, location of 
medical supervision, and an extensive range of blood biomarkers which 
indicated the presence and severity of clinical disease. Fasting plasma 
glucose and glycosylated haemoglobin (HbA1c) were used to detect 
diabetes; plasma total cholesterol, triglycerides served as markers of 
dyslipidaemia; alanine aminotransferase (ALT), total bilirubin, alkaline 
phosphatase (ALP), gamma-glutamyltransferase (GGT) and serum al-
bumin measured hepatic function; while serum albumin also served as 
an measure of acute illness. White blood cells (WBC), lymphocytes, and 
neutrophils, c-reactive protein, erythrocyte-sedimentation rate served as 
markers of inflammation. Lastly, serum urea and creatinine were mea-
sures of renal function. Serum creatinine was measured using the 
modified kinetic Jaffe method and creatinine values were calibrated to 
be traceable to an isotope dilution mass spectrometry (IDMS) reference 
measurement procedure to ensure standardization. Serum creatinine 
values were used to determine estimated glomerular filtration rate 
(eGFR) in ml/min per 1.73 m2, for patients using equations derived by 
the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) [24, 
25]. Chronic Kidney Disease was defined according to the Kidney Dis-
ease Dialysis Quality Outcome Initiative (KDOQI) guidelines based on 
eGFR measurements [26]. The location of medical supervision was 
defined as the location where the creatinine test was ordered by the 
supervising physician and categorised as; inpatient facility (IP), outpa-
tient facility (OP), general practice (GP) and emergency room (ER). 
2.5. Statistical analysis 
Serum uric acid was classified according to increments of 59.48 
µmol/L (or 1 mg/dL) for men and women. Baseline characteristics of all 
subjects and by category were summarised and described using per-
centages for categorical data, mean and standard deviation for contin-
uous variables or median and interquartile range for continuous 
variables with skewed distribution. Group comparisons for continuous 
variables were performed using the Kruskal Wallis test while group 
comparisons for categorical variables were performed with the Chi- 
square test. 
Mortality rates were calculated for the entire cohort by strata of SUA 
expressed as deaths per 1000 person-years. The association of SUA with 
mortality was explored separately for men and women using sex-specific 
strata. Cox proportional hazard regression was used to model relation-
ships of SUA with all-cause mortality adjusting for baseline character-
istics and using age as the time scale. For men, the stratum (357–416 
µmol/L) was used as the reference group given that it appeared to have 
the lowest mortality from the crude mortality analyses, while for women 
the (297–357 µmol/L) stratum was used as the reference. Patients were 
followed until death or end of study date; 31st December 2013. Cova-
riates for adjustment included demographic factors, and core laboratory 
health indicators including eGFR estimated at baseline, plasma lipid 
levels, serum albumin, haemoglobin and ALT levels. Associations of SUA 
with mortality were expressed as hazard ratios (HR) with 95% Confi-
dence Intervals (CI) in univariate and multivariable models. Schoenfeld 
tests assessed the proportional hazards assumption of the Cox models. 
The median survival age and corresponding 95% confidence intervals 
(via 1000 bootstrap replicates) were computed from the unadjusted and 
adjusted Cox models across each SUA category for men and for women; 
further details can be found in supplementary materials. To further 
examine the continuous association between SUA levels and mortality, 
we fitted a penalised spline model for SUA where the optimal spline 
smoothing parameter was selected by minimising the Akaike informa-
tion criterion (AIC). All statistical analysis was performed using R pro-
gram (version 4.0; http://www.r-project.org/). 
2.6. Sensitivity analysis 
A sensitivity analysis was conducted to explore the robustness of 
observed relationships. We investigated whether the presence of CKD as 
defined by an eGFR threshold of less than 60 ml/min/1.73 m2 modified 
the relationship between SUA and mortality as SUA has been reported to 
play a causal role in kidney injury and the presence of hyperuricemia 
may reflect poor renal function [27,28]. Effect modification was 
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explored by including cross-product interaction terms in the Cox models 
that examined the impact of baseline covariates on the SUA-mortality 
relationship. 
2.7. Ethics approval 
The study was approved by the Ethics Committee at University 
Hospital Limerick. 
3. Results 
3.1. Baseline characteristics of the population 
The construction of the final study cohort from the Midwest region of 
Ireland is shown in Fig. 1 according to the STROBE criteria. The distri-
butions of demographic characteristics and laboratory measures across 
sex-specific strata of SUA are listed separately for men (Table 1) and for 
women (Table 2). Of the 26,525 Patients, 53% were male and the mean 
(SD) baseline age was 53.8 (15.5) years. Serum uric acid levels were 
higher in men than in women and most of patients were seen in general 
practice or primary care setting. 
Among men, an increase in SUA level was positively associated with 
decreasing renal function, rising inflammatory markers (c-reactive 
protein, white blood cell count) and increasing concentration of total 
cholesterol, triglycerides, ALT and GGT levels. Serum uric acid con-
centration did not increase linearly with age in men, rather patients in 
the lowest and highest SUA strata were on average older in age. Simi-
larly, serum albumin and haemoglobin concentrations were lower at the 
extremes of the SUA categories while glycaemic markers and neutrophil 
levels were conversely higher at the extreme levels. 
In contrast to men, SUA levels increased linearly with age in women. 
Increasing SUA levels were positively associated with reduced renal 
function and serum albumin levels in women. SUA was associated with 
increased levels of inflammatory markers, serum calcium, triglycerides, 
fasting glucose, HbA1c, ALT, ALP and GGT levels. Women in the lower 
and higher SUA strata had lower haemoglobin and cholesterol levels. 
Over a median follow-up of 5.12 years (IQR, 3.06 to 6.59), there 
were 1,288 (4.9%) deaths among a cohort of 26,525 participants. 
3.2. Serum uric acid and mortality in men 
For men, crude death rates were greatest in the lowest (<238 µmol/ 
L) and highest SUA categories (>535 µmol/L) at 26.8 and 29.5 deaths 
per 1000 person-years respectively compared with 8.3 deaths per 1000 
Fig. 1. Strobe diagram for the retrospective cohort study from 2006–2013. The final dataset captured information on demographic characteristics, county of 
residence, and primary location of patient supervision, measured laboratory parameters and mortality. 
L.D. Browne et al.                                                                                                                                                                                                                              
European Journal of Internal Medicine 84 (2021) 46–55
49
person-years in the 357–416 µmol/L category (Table 3). In the unad-
justed analysis, men in the lowest and highest strata experienced 
increased risk of mortality with HR 2.35 (1.65–3.14) and HR 2.52 
(1.87–3.29) respectively compared to the referent group. (357–416 
µmol/L) With adjustment for measures of anaemia, nutrition, liver and 
kidney function, the association was attenuated but the U-shaped 
pattern with mortality persisted (Table 3); HR 2.32 (1.53–3.27) for SUA 
< 238 µmol/L and HR 2.79 (1.91–4.02) for SUA > 535 µmol/L. 
The estimated median age of survival for men in each stratum are 
shown in Fig. 2 and Table 3. Compared to the referent group, men in the 
lowest and highest strata had the lowest adjusted median ages of sur-
vival with a corresponding reduction in the median lifetime of 9.52 
(4.38, 15.53) and 11.7 years (7.27, 16.92) respectively. 
When SUA was modelled as a continuous variable using penalised 
spline regression models, a non-linear U-shaped association persisted (p- 
value for test of linearity <0.001) (Fig. 3). This U-shaped association 
between SUA levels with all-cause mortality remained consistent after 
adjusting for confounding. In the fully adjusted model, the risk of 
mortality was significantly higher for SUA levels > 454 µmol/L with a 
HR of 1.15 (1.00–1.33) and for SUA levels <304 µmol/L with a HR of 
1.12 (1.00–1.25) compared to a reference value of 370 µmol/L. 
3.3. Serum uric acid and mortality in women 
In women, unlike men, crude death rates were highest for patients 
with SUA levels in the 416-476 µmol/L and >476 µmol/L strata at 25.8 
and 44.6 deaths per 1000 person-years. In the unadjusted analysis, these 
higher SUA groups had an elevated risk of mortality with HR 1.79 
(1.23–2.41) and HR 1.89 (1.34–2.57) respectively compared to the 
referent (297–357 µmol/L); with adjustment, the association was 
attenuated with HR 1.69 (1.13–2.47) and HR 1.59 (1.02–2.33). 
Fig. 2 and Table 3 illustrate the estimated survival curves and median 
age of survival for each strata group in women. Mirroring the hazard 
ratios, the 416–476 µmol/L and >476 µmol/L groups had the lowest 
Table 1 
Baseline characteristics of Patients by Serum Uric Acid level among Men.  
Variable N Uric Acid Category P-value 
Conventional Units  <4 mg/dL 4-5 mg/dL 5-6 mg/dL 6-7 mg/dL 7-8 mg/dL 8-9 mg/dL >9 mg/dL  
SI Units  <238 µmol/L 238-297 µmol/L 297-357 µmol/L 357-416 µmol/L 416-476 µmol/L 476-535 µmol/L >535 µmol/L  
Observations n (%) 13,922 443 (3.2) 1973 (14.2) 4099 (29.4) 3985 (28.6) 2099 (15.1) 881 (6.3) 442 (3.2)  
Mean Age at baseline (SD) 13,922 57.91 (14.20) 54.05 (15.14) 53.38 (14.71) 52.91 (14.35) 53.88 (14.55) 55.40 (14.84) 57.85 (15.49) <0.001 
Age Group (years) 
18-29 945 3.61 7.5 7.51 7.23 5.91 5.11 3.62  
30-44 3,107 15.12 21.64 22.76 23.16 22.49 21.91 20.81  
45-59 5,106 37.02 34.67 35.5 38.95 37.83 35.87 31.9  
60-74 3,812 34.54 28.74 28.18 25.17 26.82 27.47 29.19  
75-84 850 9.03 6.94 5.46 4.97 6 8.17 11.99  
>84 102 0.68 0.51 0.59 0.53 0.95 1.48 2.49 <0.001 
Location of Medical Supervision a (%) 
Emergency Room (ER) 30 0.23 0.15 0.1 0.18 0.33 0.45 0.91  
General Practice (GP) 13,382 90.95 95.95 96.73 97.06 96.13 95.8 91.12  
Inpatient (IP) 219 4.98 1.67 1.51 1.15 1.34 1.25 3.87  
Outpatient (OP) 279 3.85 2.23 1.66 1.61 2.2 2.5 4.1 <0.001 
Markers of Renal Function (Median (IQR)) 
Urea (mmol/L) 13,694 4.70 (2.00) 4.90 (1.70) 5.00 (1.80) 5.20 (1.80) 5.30 (2.00) 5.70 (2.40) 6.20 (4.40) <0.001 
Serum creatinine (µmol/L) 13,922 76.00 (21.00) 81.00 (17.00) 83.00 (18.00) 86.00 (18.00) 89.00 (21.00) 93.00 (24.00) 103.50 (43.75) <0.001 
eGFR at baseline (ml/min/1.73m2) b 13,922 93.74 (20.93) 93.33 (23.27) 91.02 (22.74) 88.50 (24.99) 85.36 (27.46) 80.13 (29.70) 68.46 (40.95) <0.001 
eGFR Category  
eGFR >=90 6,651 59.37 57.78 52.01 46.8 40.92 32.35 24.21  
eGFR 60-89 6,056 36.57 38.06 42.67 45.45 47.02 49.49 36.2  
eGFR 30-59 1,097 3.84 3.8 5 7.25 11.2 15.66 31.22  
eGFR 15-29 100 0 0.25 0.27 0.38 0.86 1.82 7.92  
eGFR < 15 18 0.23 0.1 0.05 0.13 0 0.68 0.45 <0.001 
Inflammatory Markers (Median (IQR)) 
C-Reactive Protein (mg/L) 631 7.00 (12.00) 7.00 (17.75) 7.00 (13.00) 6.00 (8.00) 8.00 (13.00) 8.00 (9.75) 9.00 (9.00) 0.272 
ESR (mm/hr) 2,641 7.00 (12.00) 7.00 (8.75) 6.00 (7.00) 6.00 (7.00) 7.00 (8.00) 11.00 (11.00) 14.00 (18.00) <0.001 
White blood count (x109/L) 12,551 6.62 (2.87) 6.64 (2.61) 6.47 (2.39) 6.58 (2.26) 6.69 (2.28) 6.94 (2.39) 7.47 (2.79) <0.001 
Lymphocyte count (x109/L) 12,551 1.68 (0.88) 1.78 (0.80) 1.80 (0.75) 1.84 (0.75) 1.88 (0.74) 1.82 (0.76) 1.79 (0.88) <0.001 
Neutrophil count (x109/L) 12,551 4.00 (2.28) 3.83 (1.88) 3.71 (1.73) 3.78 (1.68) 3.81 (1.71) 4.05 (1.91) 4.43 (2.26) <0.001 
Nutritional and Metabolic Markers (Mean (SD)) 
Serum Albumin (g/L) 9,593 38.57 (5.11) 39.97 (3.71) 40.34 (3.44) 40.67 (3.33) 40.44 (3.42) 39.67 (3.90) 38.28 (4.49) <0.001 
Haemoglobin (g/dl) 12,551 14.21 (1.65) 14.70 (1.30) 14.90 (1.16) 14.99 (1.18) 14.93 (1.22) 14.82 (1.35) 14.23 (1.69) <0.001 
Serum Calcium (mmol/L) 8,945 2.30 (0.11) 2.32 (0.09) 2.32 (0.09) 2.33 (0.08) 2.33 (0.09) 2.32 (0.09) 2.31 (0.13) <0.001 
Serum Phosphorus (mmol/L) 8,420 1.13 (0.23) 1.11 (0.23) 1.08 (0.21) 1.08 (0.20) 1.08 (0.20) 1.09 (0.21) 1.17 (0.29) <0.001 
Serum Potassium (mmol/L) 11,693 4.52 (0.48) 4.59 (0.49) 4.55 (0.45) 4.56 (0.46) 4.56 (0.44) 4.56 (0.45) 4.55 (0.52) 0.148 
Lipid Markers (Mean (SD)) 
Total Cholesterol (mmol/L) 13,922 4.73(1.13) 4.89 (1.07) 5.05 (1.07) 5.16 (1.08) 5.19 (1.10) 5.22 (1.11) 5.05 (1.27) <0.001 
Triglycerides (mmol/L) 13,922 1.30 (0.85) 1.36 (1.03) 1.48 (0.97) 1.64 (1.07) 1.86 (1.15) 2.06 (1.28) 2.34 (1.47) <0.001 
Glycaemic Markers (Median (IQR)) 
HbA1c (%) 3,094 7.30 (3.25) 6.36 (2.60) 6.00 (1.40) 5.90 (1.10) 5.90 (0.98) 5.99 (0.90) 6.15 (1.24) <0.001 
Glucose (mmol/L) 8,860 5.20 (1.45) 5.10 (1.10) 5.00 (0.90) 5.10 (0.80) 5.10 (0.80) 5.20 (0.80) 5.30 (1.00) <0.001 
Markers of Liver function (Median (IQR)) 
Alanine transaminase (IU/L) 13,285 25.00 (14.00) 25.00 (13.00) 28.00 (14.00) 30.00 (17.00) 32.00 (18.00) 32.00 (21.75) 32.00 (21.00) <0.001 
Alkaline phosphatase (IU/L) 13,415 69.50 (27.00) 67.00 (23.00) 66.00 (23.00) 66.00 (23.00) 66.00 (23.00) 66.50 (24.00) 71.00 (26.00) <0.001 
γ-glutamyltransferase (IU/L) 13,382 26.00 (22.00) 24.00 (18.00) 26.00 (20.00) 29.00 (21.00) 34.00 (27.00) 37.00 (31.00) 46.00 (51.00) <0.001 
Total bilirubin (µmol/L) 13,133 12.00 (6.00) 13.00 (6.00) 14.00 (6.00) 14.00 (7.00) 14.00 (7.00) 14.00 (6.00) 14.00 (6.00) <0.001  
a Location of medical supervision refers to the location of patient when the laboratory test was conducted. 
b eGFR: Estimated glomerular filtration rate (ml/min per 1.73 m2) was based on the Chronic Kidney Disease Collaborative (CKD-EPI) equation [15]. SI: International 
System of Units. 
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adjusted median lifetimes with reductions of 5.9 years (0.97, 12.32) and 
5.1 years (0.00, 11.68) respectively compared to the referent group. 
When SUA was modelled as a continuous variable using penalised 
splines, the uric acid-mortality association was non-linear and followed 
a J-shaped pattern. With adjustment for confounding, the magnitude of 
the association was attenuated such that the risk of mortality was 
significantly elevated only for women with SUA values exceeding 409 
µmol/L, HR 1.14 (1.00–1.40) compared to a reference value of 321 
µmol/L. 
3.4. Sensitivity Analysis 
To explore the robustness of our results, we further examined 
whether the relationship between SUA and mortality differed by the 
presence of absence of CKD, where CKD was defined as eGFR less than 
60 mL/min./1.73 m2). Elevated levels of SUA remained an independent 
risk factor for all-cause mortality in patients with and without CKD. For 
men with or without CKD the p-value for the interaction = 0.57, while 
for women the p-value for the interaction = 0.15. 
Table 2 
Baseline characteristics of Patients by Serum Uric Acid level among Women.  
Variable N Uric Acid Category P- 
Value 
Conventional Units  <3 mg/dL 3-4 mg/dL 4-5 mg/dL 5-6 mg/dL 6-7 mg/dL 7-8 mg/dL >8mg/dL  














Observations n (%) 12,603 381 (3) 2538 (20.1) 4487 (35.6) 3027 (24) 1364 (10.8) 486 (3.9) 320 (2.5)  
Mean Age at baseline (SD) 12,603 47.81(16.52) 48.70 (15.53) 51.54 (15.89) 55.62 (15.62) 59.58 (15.09) 64.22 (13.36) 70.24 
(12.79) 
<0.001 
Age Group (years) 
18-29 1,220 15.75 13.83 11.23 7.93 4.25 1.03 0.62  
30-44 2,681 33.07 30.50 23.65 16.35 12.68 7.82 4.38  
45-59 4,239 28.35 31.44 35.73 35.88 33.36 28.40 15.94  
60-74 3,265 16.27 18.99 22.58 30.16 34.16 40.95 40.62  
75-84 980 4.20 4.49 5.75 7.93 12.54 17.90 29.38  
>84 218 2.36 0.75 1.07 1.75 3.01 3.91 9.06 <0.001 
Location of Medical Supervision a (%) 
Emergency Room (ER) 12 0.00 0.04 0.11 0.07 0.15 0.21 0.31  
General Practice (GP) 12,132 94.75 97.40 96.56 96.56 95.67 93.42 90.62  
Inpatient (IP) 253 3.15 1.54 1.81 1.78 2.64 3.50 4.38  
Outpatient (OP) 200 2.10 1.02 1.52 1.59 1.54 2.88 4.69 <0.001 
Markers of Renal Function (Median (IQR)) 
Urea (mmol/L) 12,458 3.70 (1.52) 3.90 (1.60) 4.30 (1.70) 4.70 (1.90) 5.10 (2.30) 5.90 (2.60) 7.90 (4.60) <0.001 
Serum creatinine (µmol/L) 12,603 61.00 
(16.00) 
63.00 (15.00) 66.00 (15.00) 70.00 (18.00) 75.00 (20.00) 79.00 (27.75) 105.00 
(48.00) 
<0.001 








>90 6,029 69.82 65.68 53.26 40.11 28.01 17.70 7.50  
60-90 5,088 27.03 30.85 40.99 46.75 48.90 43.00 22.50  
30-60 1,370 2.89 3.39 5.57 12.62 21.70 35.80 53.44  
15-30 104 0.00 0.00 0.18 0.50 1.32 2.88 15.31  
<15 12 0.26 0.08 0.00 0.03 0.07 0.62 1.25 <0.001 
Inflammatory Markers (Median (IQR)) 
C-Reactive Protein (mg/L) 814 5.50 (15.75) 7.00 (11.00) 5.00 (7.00) 6.00 (7.00) 7.00 (7.00) 5.00 (9.50) 8.50 (7.75) 0.018 
ESR (mm/hr) 2,733 9.00 (11.00) 9.00 (8.00) 9.00 (10.00) 12.00 (11.00) 13.00 (13.00) 17.00 (14.00) 23.00 
(30.25) 
<0.001 
White blood count (x109/L) 11,785 6.40 (2.67) 6.22 (2.52) 6.26 (2.42) 6.51 (2.48) 6.87 (2.38) 6.97 (2.72) 7.30 (2.65) <0.001 
Lymphocyte count (x109/L) 11,785 1.76 (0.71) 1.77 (0.76) 1.82 (0.75) 1.90 (0.79) 1.93 (0.80) 1.86 (0.85) 1.76 (0.96) <0.001 
Neutrophil count (x109/L) 11,785 3.76 (2.28) 3.62 (1.93) 3.59 (1.86) 3.71 (1.85) 4.02 (1.81) 4.01 (2.12) 4.44 (2.15) <0.001 
Nutritional and Metabolic Markers (Mean (SD)) 
Serum Albumin (g/L) 9,960 39.17 (3.88) 39.57 (3.17) 39.56 (3.21) 39.44 (3.13) 39.10 (3.31) 38.41 (3.35) 37.65 (4.06) <0.001 
Haemoglobin (g/dl) 11,785 12.94 (1.32) 13.21 (1.09) 13.40 (1.07) 13.49 (1.13) 13.52 (1.19) 13.34 (1.42) 12.87 (1.63) <0.001 
Serum Calcium (mmol/L) 9,357 2.30 (0.08) 2.31 (0.09) 2.32 (0.09) 2.33 (0.09) 2.33 (0.11) 2.34 (0.11) 2.33 (0.12) <0.001 
Serum Phosphorus (mmol/L) 8,562 1.21 (0.22) 1.21 (0.20) 1.21 (0.20) 1.21 (0.21) 1.20 (0.21) 1.21 (0.20) 1.24 (0.23) 0.647 
Serum Potassium (mmol/L) 10,653 4.50 (0.46) 4.48 (0.45) 4.52 (0.45) 4.51 (0.46) 4.48 (0.46) 4.48 (0.52) 4.51 (0.57) 0.013 
Lipid Markers (Mean (SD)) 
Total Cholesterol (mmol/L) 12,603 5.03 (0.99) 5.16 (0.96) 5.31 (1.03) 5.40 (1.09) 5.36 (1.13) 5.31 (1.16) 5.14 (1.25) <0.001 
Triglycerides (mmol/L) 12,603 1.01 (0.69) 1.02 (0.62) 1.16 (0.70) 1.43 (0.84) 1.58 (0.78) 1.76 (1.00) 1.83 (0.95) <0.001 
Glycaemic Markers (Median (IQR)) 
HbA1c (%) 2,256 5.70 (1.62) 5.60 (0.80) 5.70 (0.90) 5.80 (1.00) 6.00 (1.20) 6.20 (1.08) 6.30 (1.28) <0.001 
Glucose (mmol/L) 7,872 4.70 (0.60) 4.70 (0.70) 4.80 (0.60) 4.90 (0.70) 5.10 (0.80) 5.30 (1.10) 5.50 (1.25) <0.001 
Markers of Liver function (Median (IQR)) 
Alanine transaminase (IU/L) 12,033 18.00 (7.00) 18.00 (8.00) 20.00 (9.00) 22.00 (11.00) 23.00 (13.00) 23.00 (13.00) 20.00 
(12.25) 
<0.001 
Alkaline phosphatase (IU/L) 12,179 57.00 
(27.00) 
59.00 (24.00) 62.00 (26.00) 68.00 (27.00) 70.00 (25.50) 73.00 (29.00) 77.00 
(27.00) 
<0.001 
γ-glutamyltransferase (IU/L) 12,154 16.00 
(10.00) 
16.00 (10.00) 18.00 (13.00) 21.00 (15.00) 24.00 (20.00) 26.00 (19.50) 26.00 
(23.00) 
<0.001 
Total bilirubin (µmol/L) 11,970 10.00 (5.00) 11.00 (5.00) 11.00 (5.00) 12.00 (5.00) 12.00 (5.50) 12.00 (5.00) 12.00 (5.00) <0.001  
a Location of medical supervision refers to the location of patient when the laboratory test was conducted. 
b eGFR: Estimated glomerular filtration rate (ml/min per 1.73 m2) was based on the Chronic Kidney Disease Collaborative (CKD-EPI) equation [15], SI: International 
System of UnitsSerum uric acid and Mortality in Men. 
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4. Discussion 
In this large population-based study within the Irish health system, 
we have demonstrated that SUA concentrations are associated with 
elevated mortality risk in men and in women. The pattern of association 
between SUA and mortality differed between sexes. For men, the shape 
of the association was predominantly U-shaped with significantly 
elevated risk of mortality at the extremes of SUA with thresholds of <
304 and > 454 µmol/L. For women, the pattern of association was J- 
shaped with elevated risk of mortality for SUA levels beyond 409 µmol/L. 
The patterns of risk were not explained following adjustment for a large 
number of cardio-metabolic and inflammatory indicators. The findings 
of the present study have a number of important clinical implications. 
First, it provides a detailed analysis of the shape of the mortality pattern 
in men and in women and suggests that sex-differences exist with regard 
to SUA associated-mortality risk and threshold values. Second, it de-
scribes the range of SUA levels associated with optimal survival for 
patients and for the first time highlights important reductions in survival 
times associated with values outside these ranges. 
To the best of our knowledge, it remains unproven whether SUA is an 
independent risk factor for mortality and what specific threshold values 
if any are associated with elevated risk. In this cohort study, we explored 
this hypothesis among patients within the Irish health system while 
taking into consideration concurrent risks from a wide range of valid 
cardio-metabolic and renal indicators. Our analysis revealed 
significantly higher risks of mortality in men with SUA > 424 µmol/L 
and for women with SUA > 352 µmol/L in unadjusted models. Inter-
estingly, these cut-points are comparable to published sex-specific cut- 
offs for defining hyperuricaemia in the general population [>416 (7 mg/ 
dL) μmol/L in men and >357 μmol/L (6 mg/dL)) in women. With 
adjustment for a large set of metabolic biomarkers, the risks were 
marginally attenuated but nevertheless remained significant at thresh-
olds of 454 µmol/L (7.6 mg/dL) and 409 µmol/L (6.9 mg/dL) for men 
and women, respectively. By adjusting for potential confounders and 
modelling SUA both as categorical [59.4 8 µmol/L (1 mg/dL) in-
crements] and as a nonlinear continuous variable, our large cohort study 
confirmed that hyperuricemia was independently associated with mor-
tality in both men and women. Whether these mortality risk thresholds 
extend to other specific patient populations warrants additional inves-
tigation. A recent study by Virdis et al reported a linear association of 
SUA with mortality and sex-specific thresholds of 321 μmol/L (5.4 mg/ 
dL) and 279 μmol/L (4.7 mg/dL) in men and women respectively, values 
which were significantly lower than our reported thresholds [29]. We 
speculate that these reported differences in SUA thresholds for mortality 
between studies may reflect inherent differences in the underlying 
population at risk and the relative extent of adjustment for confounders. 
To date studies of the relationship between SUA and mortality have 
yielded conflicting results and have fuelled debate to whether both low 
and high levels of SUA are deleterious to an individual’s health [8,10,14, 
30–32]. Among women, our findings confirm the presence of a J-shaped 
Table 3 
Relationship of Serum Uric Acid with All-Cause Mortality among Irish Men and Women in the Health System.  
Men Uric Acid Category 
Conventional Units <4 mg/dL 4-5 mg/dL 5-6 mg/dL 6-7 mg/dL 7-8 mg/dL 8-9 mg/dL >9 mg/dL 
SI Units <238 µmol/L 238-297 µmol/L 297-357 µmol/L 357-416 µmol/ 
L 
416-476 µmol/L 476-535 µmol/L >535 µmol/L 
Observations 443 1,973 4,099 3,985 2,099 881 442 
Person years 2015.8 9448.5 19388.3 18828.3 9816.6 3857.6 1900.4 
Deaths 54 119 180 156 99 61 56 
Crude Mortality rate per 1,000 
pyrs. 
26.8 12.6 9.3 8.3 10.1 15.8 29.5 
Hazard Ratio for all-cause mortality (95% CI) 
Unadjusted 2.35 (1.65-3.14) 1.3 (1.03-1.63) 1.05 (0.86-1.3) 1.00 
(Reference) 
1.12 (0.87-1.42) 1.5 (1.08-1.95) 2.52 (1.87-3.29) 
Multivariate Adjusted a 2.32 (1.53-3.27) 1.24 (0.91-1.65) 1.19 (0.91-1.51) 1.00 
(Reference) 
1.25 (0.9-1.66) 1.34 (0.89-1.94) 2.79 (1.91-4.02) 
Reduction in Median Survival Time, years (95% CI) 




− 0.50 (1.77, 
-2.94) 






Multivariate Adjusted a ¡9.52 (-4.38, 
-15.53) 
− 2.31 (1.18, 
-7.22) 
− 1.82 (1.20, 
-6.82) 
0 − 2.40 (1.16, 
-7.09) 




Women Uric Acid Category 
Conventional Units <3 mg/dL 3-4 mg/dL 4-5 mg/dL 5-6 mg/dL 6-7 mg/dL 7-8 mg/dL >8 mg/dL 
SI Units <178µmol/L 178-238 µmol/L 238–297 µmol/L 297–357 µmol/ 
L 
357–416 µmol/L 416–476 µmol/L >476 µmol/L 
Observations 381 2,538 4,487 3,027 1,364 486 320 
Person years 1768.0 12018.5 21143.8 14405.5 6612.0 2250.5 1390.7 
Deaths 15 64 148 129 87 58 62 
Crude Mortality rate per 1,000 
pyrs. 
8.5 5.3 7.0 9.0 13.2 25.8 44.6 
Hazard Ratio for all-cause mortality (95% CI) 
Unadjusted 1.46 (0.75-2.36) 0.96 (0.69-1.29) 1.03 (0.80-1.30) 1.00 
(Reference) 
1.07 (0.80-1.39) 1.79 (1.23-2.41) 1.89 (1.34-2.57) 
Multivariate Adjusted a 1.77 (0.86-2.93) 1.15 (0.81-1.60) 1.17 (0.88-1.54) 1.00 
(Reference) 
1.15 (0.83-1.54) 1.69 (1.13-2.47) 1.59 (1.02-2.33) 
Reduction in Median Survival Time, years (95% CI) 
Unadjusted − 2.81 (2.61, -7.7) 0.43 (3.23, 
-2.12) 
− 0.19 (1.87, 
-2.35) 






Multivariate Adjusted a − 5.98 (1.30, 
-13.84) 
− 1.60 (3.08, 
-8.28) 
− 1.85 (1.47, 
-8.28) 






Median survival time was determined by Cox regression estimate of the survival function using age as a time scale. Multivariate models a were adjusted for baseline 
covariates of eGFR, Cholesterol, Triglycerides, Haemoglobin, Albumin and Alanine Aminotransferase (ALT). Triglycerides and ALT were logarithmically transformed, 
haemoglobin and albumin were modelled as tertiles. To estimate the median reduction in lifetime’s, the adjusted covariates were set to their mean values for 
continuous variables and the mode for categorical variables. SI; International System of Units.Sensitivity Analysis. 
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pattern of association suggesting that only high levels of SUA are dele-
terious to health. Despite adjustment for measures of kidney function, 
hyperlipidaemia, anaemia, serum albumin and surrogate markers of 
obesity, metabolic syndrome, and inflammation [33–35], the mortality 
risks remained significant for women with elevated levels of SUA. For 
men, we observed a U-shaped association between SUA and mortality; 
even with adjustment for these core valid measures of cardio-metabolic 
dysregulation, higher mortality was also observed with low SUA levels. 
These patterns of association extend the findings of Cho et al, and Tseng 
et al reported in South Korean and Taiwanese cohorts [8,10]. 
Unlike previous published studies, this is the first study to yield 
detailed survival statistics for SUA concentrations among men and 
women. Importantly, we reveal that for Irish men in the health system, 
the median survival age was reduced by 9.5 and 11.7 years respectively 
for SUA values in the lowest and highest strata versus the normal range. 
Similarly, for women, we found that the median survival in the highest 
strata was reduced by 5 years compared to women with SUA in the 
normal range. Our study has drawn attention to the fact that extreme 
SUA levels are associated diminished patient survival taking other 
mortality risk factors into consideration. These findings might suggest 
that targeting SUA levels to normal ranges should be a principal goal to 
extend patient survival. However, whether this would confer an 
absolute survival benefit in all patient subgroups remains to be proven 
from appropriately designed clinical trials [36,37]. 
Whether uric acid contributes directly to mortality or is a surrogate 
of ambient disease remains an active area of debate as the factors often 
associated with low and high uric acid levels may independently 
contribute to death risk. As carefully designed clinical trials continue to 
explore the implications of lowering SUA levels with intensive urate 
lowering therapy on outcomes, we would caution against the uncondi-
tional lowering of SUA in the management for hyperuricemia [38]. We 
suggest that optimal SUA levels should fall between 304 and 454 µmol/L 
for men and below 409 µmol/L for women as these ranges were asso-
ciated with the greatest survival. 
The relative contribution of uric acid’s antioxidant properties and its 
role in endothelial dysfunction may explain the U or J-shaped association 
between SUA levels and mortality observed in this study. It has been 
reported that increased SUA levels are associated with increased anti- 
oxidant capacity [39]. However, these protective, antioxidant effects 
may be overwhelmed by other, more harmful, effects of serum uric acid 
at markedly elevated levels. Oxidative stress with activation of the 
renin–angiotensin system in human vascular endothelial cells is a key 
mechanism of uric acid induced endothelial dysfunction [30,40]. High 
levels of uric acid may contribute to high mortality through direct injury 
Fig. 2. Estimated survival curves using age as 
time scale for the unadjusted association be-
tween SUA strata and all-cause mortality in 
men (a) and women (b). Estimated survival 
curves for the association between SUA strata 
and all-cause mortality in men (c) and women 
(d) adjusting for eGFR, Cholesterol, Tri-
glycerides, Haemoglobin, Albumin & Alanine 
Aminotransferase. Triglycerides and ALT were 
logarithmically transformed, haemoglobin and 
albumin were modelled as tertiles. To estimate 
the median lifetime’s, the adjusted covariates 
were set to their mean values for continuous 
variables and the mode for categorical 
variables.   
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Fig. 3. The unadjusted & multivariable-adjusted hazard ratios for all-cause mortality by serum uric acid level among Men and Women. The top panel contains the 
distribution of uric acid as a percentage of the population (Bindwidth=10 µmol/L. Solid line (—) denotes Hazard ratio and dash line (- - -) denotes 95% confidence 
intervals (CIs). Filled circles denote statistical significance (P<0.05) compared with the reference (blue circle). Estimates are based on unadjusted and adjusted 
penalised spline models for the association between SUA and all-cause mortality with age as the time scale. Hazard ratios were adjusted for eGFR, Cholesterol, 
Triglycerides, Haemoglobin, Albumin & Alanine Aminotransferase. 
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to the endothelium, local and systemic vasoconstriction, secondary hy-
pertension and progressive kidney disease [41,42]. Previous studies 
have linked elevations in inflammatory markers to elevated SUA levels. 
Uric acid may induce both endothelial dysfunction and vascular 
inflammation, which concomitantly may lead to accelerated athero-
sclerosis [19,43]. Several explanations have been proposed to elucidate 
a potential association between low levels of serum uric acid and mor-
tality. Recent evidence suggests that low SUA may be a marker for poor 
nutritional status in certain populations [8,13]. Interestingly, in our 
study, low SUA levels were associated with a higher proportion of 
cancer-related mortality whereas high SUA levels were associated with 
higher proportion of cardiovascular-related mortality (Supplementary 
Figures 1 & 2.) Patients with cancer often suffer from poor nutrition, 
therefore, it is plausible that protein-energy wasting resulted in both low 
SUA levels and higher mortality among these patients. The link between 
low SUA and mortality may parallel that of deficiencies of antioxidant 
and anti-inflammatory vitamins C and D [8,44,45]. SUA is the most 
abundant free radical ‘scavenger’ found in human blood [46]. Depleted 
levels may enhance susceptibility to a range of age-related diseases and 
increase mortality risk. Therefore, paradoxically, the opposing 
oxidant-antioxidant properties of uric acid may explain both the U and 
J-shaped associations between SUA levels and mortality. Future in-
vestigations are needed to assess the biological mechanisms that may 
clarify the link between uric acid levels, disease progression and sub-
sequent mortality risk. 
This study has several limitations. First, we did not adjust for lifestyle 
factors including diet, smoking, alcohol use, physical activity and 
medication history, although many of these are likely to influence the 
clinical biomarkers included in our analysis. Data on urate-lowering 
medications were not available. We used a single assessment of uric 
acid levels at baseline and did not incorporate changes in uric acid or 
other changes in lifestyle factors and covariates during follow-up. 
Fluctuations in uric acid are multifactorial: body mass index, waist 
circumference, blood pressure, insulin resistance, renal disease, diet, 
medication use, and genetic factors are all known to contribute to the 
variability of uric acid levels. Elevated SUA levels are closely related to 
increased BMI, which is also significantly associated with various CVD 
risk factors which cause endothelial dysfunction, depleted vasomotor 
reactivity and arterial stiffness. Such pathophysiology induced by 
increased BMI may be greater than that of elevated SUA levels. Finally, 
the subjects included in this study were Irish men and women who 
received healthcare within the Irish health system and may not be 
generalisable to other populations. The estimation of the median age of 
survival assumes that age-specific mortality rates in the future will be 
similar to those today. Although it represents the best information 
available to us currently, it does not consider recent and future im-
provements in care and treatment that will impact survival. 
Despite these limitations, the present study had several strengths. 
This is the first large-scale cohort study to examine the association of 
SUA level with all-cause mortality in the Irish health system. Utilisation 
of a 26, 525 patient cohort, comprising of a high proportion of middle 
aged and elderly patients with an 8-year study period provided adequate 
statistical power for the analysis of long-term mortality outcomes. Date 
of death was accurately identified from the Central Statistics Office 
Registry and the survival status of all participants was recorded. Using 
sex stratifications and providing SUA levels using strata and as a non- 
linear continuum, our findings are more applicable to clinical knowl-
edge and decision making by providing reference ranges relevant to an 
Irish context, and will allow clinically sensible cut-points to be 
compared between different studies. 
5. Conclusion 
This study provides evidence to support non-linear associations of 
SUA with mortality in men and women in the Irish health system. Pa-
tients with extreme values of SUA contribute to mortality and to 
shortened life spans. The range of SUA values associated with greatest 
survival benefit and lowest mortality risk was observed between 304- 
454 µmol/l for men and below 409 µmol/l for women. Given that the 
incidence and clinical presentations for cardiometabolic diseases differ 
across the life course of men and women, SUA may play a role as a 
prognostic indicator to aid screening. 
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[6] Piepoli MF, Salvioni E, Corrà U, et al. Increased serum uric acid level predicts poor 
prognosis in mildly severe chronic heart failure with reduced ejection fraction. An 
analysis from the MECKI score research group. Eur J Intern Med 2020;72:47–52. 
https://doi.org/10.1016/j.ejim.2019.11.003. 
[7] Borghi C, Agabiti-Rosei E, Johnson RJ, et al. Hyperuricaemia and gout in 
cardiovascular, metabolic and kidney disease. Eur J Intern Med 2020;80:1–11. 
https://doi.org/10.1016/j.ejim.2020.07.006. 
[8] Tseng WC, Chen YT, Ou SM, et al. U-shaped association between serum uric acid 
levels with cardiovascular and all-cause mortality in the elderly: the role of 
malnourishment. Journal of the American Heart Association 2018;7(4). https:// 
doi.org/10.1161/JAHA.117.007523. 
L.D. Browne et al.                                                                                                                                                                                                                              
European Journal of Internal Medicine 84 (2021) 46–55
55
[9] Lamacchia O, Fontana A, Pacilli A, et al. On the non-linear association between 
serum uric acid levels and all- cause mortality rate in patients with type 2 diabetes 
mellitus. Atherosclerosis 2017;260:20–6. https://doi.org/10.1016/j. 
atherosclerosis.2017.03.008. 
[10] Cho SK, Chang Y, Kim I, Ryu S. U-Shaped Association Between Serum Uric Acid 
Level and Risk of Mortality: a Cohort Study. Arthritis Rheumatol 2018;70(7): 
1122–32. https://doi.org/10.1002/art.40472. 
[11] Dahle DO, Jenssen T, Holdaas H, et al. Uric acid has a J-shaped association with 
cardiovascular and all-cause mortality in kidney transplant recipients. Clinical 
Transplantation 2014;28(1):134–40. https://doi.org/10.1111/ctr.12290. 
[12] Bae E, Cho HJ, Shin N, et al. Lower serum uric acid level predicts mortality in 
dialysis patients. Med (United States) 2016;95(24):1–9. https://doi.org/10.1097/ 
MD.0000000000003701. 
[13] Park C, Obi Y, Streja E, et al. Serum uric acid, protein intake and mortality in 
hemodialysis patients. Nephrology, Dialysis, Transplantation 2017;32(10):1750–7. 
https://doi.org/10.1093/ndt/gfw419. 
[14] Kim CS, Jin DC, Yun YC, Bae EH, Ma SK, Kim SW. Relationship between serum uric 
acid and mortality among hemodialysis patients: retrospective analysis of Korean 
end-stage renal disease registry data. Kidney Res Clin Pract 2017;36(4):368–76. 
https://doi.org/10.23876/j.krcp.2017.36.4.368. 
[15] Davies KJA, Sevanian A, Muakkassah-Kelly SF, Hochstein P. Uric acid-iron ion 
complexes. A new aspect of the antioxidant functions of uric acid. Biochemical 
Journal 1986;235(3):747–54. https://doi.org/10.1042/bj2350747. 
[16] Hink HU, Santanam N, Dikalov S, et al. Peroxidase properties of extracellular 
superoxide dismutase role of uric acid in modulating in vivo activity. 
Arteriosclerosis, Thrombosis, and Vascular Biology 2002;22(9):1402–8. https:// 
doi.org/10.1161/01.ATV.0000027524.86752.02. 
[17] Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant 
defense in humans against oxidant- and radical-caused aging and cancer: a 
hypothesis. Pnas 1981;78(11):6858–62. https://doi.org/10.1073/ 
pnas.78.11.6858. 
[18] Maxwell SRJ, Thomason H, Sandler D, et al. Antioxidant status in patients with 
uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. 
European Journal of Clinical Investigation 1997;27(6):484–90. https://doi.org/ 
10.1046/j.1365-2362.1997.1390687.x. 
[19] Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic 
antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/ 
nitrosative stress. Am J Physiol - Cell Physiol 2007;293(2):584–96. https://doi. 
org/10.1152/ajpcell.00600.2006. 
[20] Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the 
proinflammatory endocrine imbalance in the adipose tissue in a murine model of 
the metabolic syndrome. Diabetes 2011;60(4):1258–69. https://doi.org/10.2337/ 
db10-0916. 
[21] Pitocco D, Di Stasio E, Romitelli F, et al. Hypouricemia linked to an overproduction 
of nitric oxide is an early marker of oxidative stress in female subjects with type 1 
diabetes. Diabetes Metabolism Research and Reviews 2008;24(4):318–23. https:// 
doi.org/10.1002/dmrr.814. 
[22] Kuwabara M, Niwa K, Ohtahara A, et al. Prevalence and complications of 
hypouricemia in a general population: a largescale cross-sectional study in Japan. 
Plos One 2017;12(4):1–13. https://doi.org/10.1371/journal.pone.0176055. 
[23] Stack AG, Casserly LF, Cronin CJ, et al. Prevalence and variation of Chronic Kidney 
Disease in the Irish health system: initial findings from the National Kidney Disease 
Surveillance Programme. Bmc Nephrology [Electronic Resource] 2014;15:185. 
https://doi.org/10.1186/1471-2369-15-185. 
[24] Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular 
filtration rate. Annals of Internal Medicine 2009;150(9):604–12. https://doi.org/ 
10.7326/0003-4819-150-9-200905050-00006. 
[25] Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate 
method to estimate glomerular filtration rate from serum creatinine: a new 
prediction equation. Modification of Diet in Renal Disease Study Group. Annals of 
Internal Medicine 1999;130(6):461–70. doi:199903160-00002 [pii]. 
[26] Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I 
epidemiologic follow-up study, 1971-1992. National Health and Nutrition 
Examination Survey. Jama 2000;283(18):2404–10. https://doi.org/10.1001/ 
jama.283.18.2404. 
[27] Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E. Uric acid 
and chronic kidney disease: which is chasing which? Nephrology, Dialysis, 
Transplantation 2013;28(9):2221–8. https://doi.org/10.1093/ndt/gft029. 
[28] Madero M, Sarnak MJ, Wang X, et al. Uric Acid and Long-term Outcomes in CKD. 
American Journal of Kidney Diseases 2009;53(5):796–803. https://doi.org/ 
10.1053/j.ajkd.2008.12.021. 
[29] Virdis A, Masi S, Casiglia E, et al. Identification of the Uric Acid Thresholds 
Predicting an Increased Total and Cardiovascular Mortality over 20 Years. 
Hypertension 2020:302–8. https://doi.org/10.1161/ 
HYPERTENSIONAHA.119.13643. Published online. 
[30] Gwag H Bin, Yang JH, Park T.K., et al. Uric Acid Level Has a U-shaped Association 
with Clinical Outcomes in Patients with Vasospastic Angina. 2017;16(12). 
[31] Zhang W, Iso H, Murakami Y, et al. Serum Uric Acid and Mortality Form 
Cardiovascular Disease: EPOCH-JAPAN Study. Journal of Atherosclerosis and 
Thrombosis 2016;23(6):692–703. https://doi.org/10.5551/jat.31591. 
[32] Kuo CF, See LC, Yu KH, Chou IJ, Chiou MJ, Luo SF. Significance of serum uric acid 
levels on the risk of all-cause and cardiovascular mortality. Rheumatol (United 
Kingdom) 2013;52(1):127–34. https://doi.org/10.1093/rheumatology/kes223. 
[33] Kim C., Park J., Lee K., Kim J., Kim H. Association of serum γ -glutamyltransferase 
and alanine aminotransferase activities with risk of type 2 diabetes mellitus 
independent of fatty liver. 2009;(March 2008):64–69. doi:10.1002/dmrr. 
[34] Villegas R, Xiang Y-B, Elasy T, et al. Liver Enzymes, Type 2 Diabetes, and Metabolic 
Syndrome in Middle-Aged, Urban Chinese Men. Metab Syndr Relat Disord 2011;9 
(4):305–11. https://doi.org/10.1089/met.2011.0016. 
[35] Ko S., Baeg M.K., Han K., Ko S., Ahn Y. Increased liver markers are associated with 
higher risk of type 2 diabetes. 2015;21(24):7478–7487. doi:10.3748/wjg.v21. 
i24.7478. 
[36] Nouri-Majalan N, Ardakani EF, Forouzannia K, Moshtaghian H. Effects of 
allopurinol and vitamin E on renal function in patients with cardiac coronary 
artery bypass grafts. Vasc Health Risk Manag 2009;5:489–94. https://doi.org/ 
10.2147/vhrm.s5761. 
[37] Srivastava A, Palsson R, Leaf DE, et al. Uric Acid and Acute Kidney Injury in the 
Critically Ill. Kidney Med 2019;1(1):21–30. https://doi.org/10.1016/j. 
xkme.2019.01.003. 
[38] Kang E, Hwang SS, Kim DK, et al. Sex-specific relationship of serum uric acid with 
all-cause mortality in adults with normal kidney function: an observational study. 
Journal of Rheumatology 2017;44(3):380–7. https://doi.org/10.3899/ 
jrheum.160792. 
[39] Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum 
antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000. https:// 
doi.org/10.1016/S0021-9150(99)00214-2. Published online. 
[40] Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial 
dysfunction. Kidney International 2005;67(5):1739–42. https://doi.org/10.1111/ 
j.1523-1755.2005.00273.x. 
[41] Sánchez-Lozada LG, Tapia E, Santamaría J, et al. Mild hyperuricemia induces 
vasoconstriction and maintains glomerular hypertension in normal and remnant 
kidney rats. Kidney International 2005;67(1):237–47. https://doi.org/10.1111/ 
j.1523-1755.2005.00074.x. 
[42] Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal 
arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol - 
Ren Physiol 2002;282(6 51–6):991–7. https://doi.org/10.1152/ 
ajprenal.00283.2001. 
[43] Sautin YY, Johnson RJ. URIC ACID: THE OXIDANT–ANTIOXIDANT PARADOX 
Yuri. Nucleosides, Nucleotides & Nucleic Acids 2010;27(6):608–19. https://doi. 
org/10.1080/15257770802138558.URIC. 
[44] Juraschek SP, Miller ER, Gelber AC. Effect of oral vitamin C supplementation on 
serum uric acid: a meta-analysis of randomized controlled trials. Arthritis Care Res 
(Hoboken) 2011;63(9):1295–306. https://doi.org/10.1002/acr.20519. 
[45] Peng H, Li H, Li C, Chao X, Zhang Q, Zhang Y. Association between Vitamin D 
Insufficiency and Elevated Serum Uric Acid among Middle-Aged and Elderly 
Chinese Han Women. Plos One 2013;8(4). https://doi.org/10.1371/journal. 
pone.0061159. 
[46] Glantzounis G, Tsimoyiannis E, Kappas A, Galaris D. Uric Acid and Oxidative 
Stress. Current Pharmaceutical Design 2005. https://doi.org/10.2174/ 
138161205774913255. Published online. 
L.D. Browne et al.                                                                                                                                                                                                                              
